Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (18 quarters reported)
$175M in Q4 2013 → $152M now. Hover for any quarter.
As reported for the quarter ended March 31, 2018. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr Put | 8.7% | New | 50,000 | $13.2M |
| ET Esperion Therapeutics Inc Ne | 4.8% | Trimmed 39% | 100,000 | $7.23M |
| I Immunomedics Inc | 3.8% | Trimmed 11% | 400,000 | $5.84M |
| GB Global Blood Therapeutics In | 3.7% | Trimmed 8.0% | 115,000 | $5.56M |
| Humana Inc | 3.5% | Trimmed 11% | 20,000 | $5.38M |
| Biogen Inc | 3.2% | Trimmed 20% | 17,500 | $4.79M |
| Merck & Co Inc | 2.9% | Unchanged | 80,000 | $4.36M |
| AP Arena Pharmaceuticals Inc | 2.6% | Added 100% | 100,000 | $3.95M |
| SP Shire PLC | 2.5% | New | 25,000 | $3.74M |
| CO Clovis Oncology Inc | 2.4% | Added 17% | 70,000 | $3.7M |
| ET Esperion Therapeutics Inc Ne Put | 2.4% | New | 50,000 | $3.62M |
| Anaptysbio Inc | 2.2% | Trimmed 19% | 32,500 | $3.38M |
| CC Cigna Corporation | 2.2% | Trimmed 20% | 20,000 | $3.36M |
| MN Mylan N V | 2.2% | Added 100% | 80,000 | $3.29M |
| CD Centene Corp Del | 2.1% | New | 30,000 | $3.21M |
| Bristol Myers Squibb Co | 2.1% | Unchanged | 50,000 | $3.16M |
| AP Alexion Pharmaceuticals Inc | 2.0% | New | 27,500 | $3.07M |
| UP Ultragenyx Pharmaceutical In | 2.0% | Added 20% | 60,000 | $3.06M |
| AL Abbott Labs | 2.0% | Trimmed 33% | 50,000 | $3M |
| LA Laboratory Corp Amer Hldgs | 1.9% | New | 17,500 | $2.83M |
| Adma Biologics Inc | 1.8% | Unchanged | 600,000 | $2.76M |
| Dexcom Inc | 1.7% | New | 35,000 | $2.6M |
| CB Catalyst Biosciences Inc | 1.7% | New | 100,000 | $2.58M |
| T Tesaro Inc | 1.7% | Added 29% | 45,000 | $2.57M |
| ZP Zosano Pharma Corp | 1.7% | New | 500,000 | $2.52M |
| Sangamo Therapeutics Inc | 1.6% | Trimmed 17% | 125,000 | $2.38M |
| GP Glaxosmithkline PLC | 1.5% | Added 100% | 60,000 | $2.34M |
| Rocket Pharmaceuticals Inc | 1.5% | New | 125,000 | $2.34M |
| MC Medicines Co | 1.5% | Added 17% | 70,000 | $2.31M |
| AB Armo Biosciences Inc | 1.5% | New | 60,000 | $2.25M |
| SS SPDR Series Trust Put | 1.4% | New | 25,000 | $2.19M |
| SO Sierra Oncology Inc | 1.4% | Added 25% | 1,000,000 | $2.07M |
| DP Diplomat Pharmacy Inc | 1.3% | Added 100% | 100,000 | $2.02M |
| M Myokardia Inc | 1.3% | Trimmed 20% | 40,000 | $1.95M |
| Cytomx Therapeutics Inc | 1.2% | Trimmed 13% | 65,000 | $1.85M |
| Iovance Biotherapeutics Inc | 1.1% | New | 100,000 | $1.69M |
| Mirati Therapeutics Inc | 1.1% | New | 55,000 | $1.69M |
| Karyopharm Therapeutics Inc | 1.1% | Trimmed 58% | 125,000 | $1.68M |
| Viking Therapeutics Inc | 1.1% | Added 67% | 375,000 | $1.64M |
| AP Arrowhead Pharmaceuticals In | 0.9% | New | 200,000 | $1.44M |
| Merus N V | 0.9% | Trimmed 25% | 75,000 | $1.39M |
| Voyager Therapeutics Inc | 0.9% | Added 40% | 70,000 | $1.32M |
| A Achaogen Inc | 0.9% | Added 33% | 100,000 | $1.3M |
| CI Corium Intl Inc | 0.8% | Added 22% | 110,000 | $1.26M |
| Incyte Corp | 0.8% | Added 50% | 15,000 | $1.25M |
| Catalent Inc | 0.8% | Unchanged | 30,000 | $1.23M |
| Adverum Biotechnologies Inc | 0.8% | Unchanged | 200,000 | $1.16M |
| C Cerner Corp | 0.8% | New | 20,000 | $1.16M |
| Xencor Inc | 0.7% | New | 35,000 | $1.05M |
| Kura Oncology Inc | 0.6% | New | 50,000 | $938K |
| SG Seattle Genetics Inc | 0.6% | New | 17,500 | $916K |
| SP Spectrum Pharmaceuticals Inc | 0.5% | New | 50,000 | $805K |
| D Dermira Inc | 0.5% | Unchanged | 100,000 | $799K |
| Assembly Biosciences Inc | 0.5% | New | 15,000 | $737K |
| AP Adamas Pharmaceuticals Inc | 0.5% | New | 30,000 | $717K |
| Exelixis Inc | 0.4% | New | 30,000 | $665K |
| Affimed N V | 0.4% | New | 300,000 | $555K |
| Scynexis Inc | 0.4% | Added 60% | 400,000 | $536K |
| OP Oncomed Pharmaceuticals Inc | 0.3% | Unchanged | 150,000 | $477K |
| KG K2m Group Hldgs Inc | 0.3% | Trimmed 86% | 25,000 | $474K |
Showing top 60 of 62 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended March 31, 2018 · filed May 15, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | New | +50,000 | +$13.2M | 8.7% |
| C Celgene Corp | Exited | −75,000 | −$7.83M | — |
| AP Aerie Pharmaceuticals Inc | Exited | −85,000 | −$5.08M | — |
| Abbvie Inc | Exited | −50,000 | −$4.84M | — |
| ET Esperion Therapeutics Inc Ne | Trimmed | −65,000 | −$4.7M | 4.8% |
| SP Shire PLC | New | +25,000 | +$3.74M | 2.5% |
| ET Esperion Therapeutics Inc Ne | New | +50,000 | +$3.62M | 2.4% |
| CD Centene Corp Del | New | +30,000 | +$3.21M | 2.1% |
| AP Alexion Pharmaceuticals Inc | New | +27,500 | +$3.07M | 2.0% |
| KG K2m Group Hldgs Inc | Trimmed | −150,000 | −$2.84M | 0.3% |
Showing the 10 largest of 78 changes.
quarter ended December 31, 2017 · filed February 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Alexion Pharmaceuticals Inc | Exited | −40,000 | −$5.61M | — |
| Humana Inc | New | +22,500 | +$5.58M | 3.6% |
| AN Aetna Inc New | Exited | −28,500 | −$4.53M | — |
| LE Lilly Eli & Co | Exited | −40,000 | −$3.42M | — |
| CO Clovis Oncology Inc | Trimmed | −50,000 | −$3.4M | 1.1% |
| Glaukos Corp | Exited | −100,000 | −$3.3M | — |
| AP Acceleron Pharma Inc | Exited | −70,000 | −$2.61M | — |
| F Fibrogen Inc | Exited | −40,000 | −$2.15M | — |
| M Myokardia Inc | New | +50,000 | +$2.11M | 1.4% |
| Cymabay Therapeutics Inc | Exited | −250,000 | −$2.02M | — |
Showing the 10 largest of 80 changes.
quarter ended September 30, 2017 · filed November 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SP Shire PLC | Exited | −40,000 | −$6.61M | — |
| Merck & Co Inc | Exited | −100,000 | −$6.41M | — |
| CO Clovis Oncology Inc | New | +75,000 | +$6.18M | 3.4% |
| AP Allergan PLC | Exited | −25,000 | −$6.08M | — |
| S Spectranetics Corp | Exited | −110,000 | −$4.22M | — |
| Biogen Inc | Added | +12,500 | +$3.91M | 3.5% |
| CO Clovis Oncology Inc | Exited | −40,000 | −$3.75M | — |
| S Sanofi | Exited | −75,000 | −$3.59M | — |
| Bristol Myers Squibb Co | New | +55,000 | +$3.51M | 2.0% |
| Astrazeneca PLC | Exited | −100,000 | −$3.41M | — |
Showing the 10 largest of 83 changes.
quarter ended June 30, 2017 · filed August 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Exited | −50,000 | −$11.8M | — |
| Amgen Inc | Exited | −50,000 | −$8.2M | — |
| Merck & Co Inc | New | +100,000 | +$6.41M | 3.6% |
| LE Lilly Eli & Co | New | +50,000 | +$4.12M | 2.3% |
| MC Medicines Co | Trimmed | −100,000 | −$3.8M | 3.2% |
| CO Clovis Oncology Inc | New | +40,000 | +$3.75M | 2.1% |
| S Sanofi | New | +75,000 | +$3.59M | 2.0% |
| SP Shire PLC | Trimmed | −21,250 | −$3.51M | 3.7% |
| Astrazeneca PLC | New | +100,000 | +$3.41M | 1.9% |
| CC Cigna Corporation | New | +17,500 | +$2.93M | 1.7% |
Showing the 10 largest of 80 changes.
quarter ended March 31, 2017 · filed May 15, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | New | +50,000 | +$11.8M | 5.8% |
| SP Shire PLC | New | +61,250 | +$10.7M | 5.3% |
| Biogen Inc | Trimmed | −25,000 | −$6.84M | 1.4% |
| AN Aetna Inc New | New | +50,000 | +$6.38M | 3.2% |
| UP Ultragenyx Pharmaceutical In | Trimmed | −85,000 | −$5.76M | 2.5% |
| ZB Zimmer Biomet Hldgs Inc | Trimmed | −35,000 | −$4.27M | 0.9% |
| Karyopharm Therapeutics Inc | New | +275,000 | +$3.53M | 1.7% |
| MR Mazor Robotics Ltd | Trimmed | −117,000 | −$3.48M | 0.9% |
| IT Ishares Tr | Exited | −25,000 | −$3.37M | — |
| CC Cigna Corporation | Exited | −25,000 | −$3.34M | — |
Showing the 10 largest of 79 changes.
quarter ended December 31, 2016 · filed February 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CO Clovis Oncology Inc | Trimmed | −250,000 | −$11.1M | 2.0% |
| GP Gw Pharmaceuticals PLC | Exited | −65,000 | −$8.63M | — |
| Pfizer Inc | Exited | −250,000 | −$8.47M | — |
| C Celgene Corp | Exited | −75,000 | −$7.84M | — |
| Biogen Inc | Exited | −25,000 | −$7.83M | — |
| LE Lilly Eli & Co | Exited | −75,000 | −$6.02M | — |
| GB Global Blood Therapeutics In | Exited | −100,000 | −$5.25M | — |
| Alnylam Pharmaceuticals Inc | Exited | −75,000 | −$5.08M | — |
| Exelixis Inc | Exited | −350,000 | −$4.48M | — |
| AL Abbott Labs | New | +115,000 | +$4.42M | 2.6% |
Showing the 10 largest of 89 changes.
quarter ended September 30, 2016 · filed November 14, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SP Shire PLC | Exited | −60,000 | −$11M | — |
| GP Gw Pharmaceuticals PLC | New | +65,000 | +$8.63M | 3.1% |
| CO Clovis Oncology Inc | Added | +235,000 | +$8.47M | 4.2% |
| C Celgene Corp | New | +75,000 | +$7.84M | 2.8% |
| Biogen Inc | New | +25,000 | +$7.83M | 2.8% |
| BI Baxter Intl Inc | Exited | −135,000 | −$6.11M | — |
| LE Lilly Eli & Co | New | +75,000 | +$6.02M | 2.2% |
| Gilead Sciences Inc | Trimmed | −75,000 | −$5.93M | 1.7% |
| AP Alexion Pharmaceuticals Inc | Exited | −50,000 | −$5.84M | — |
| A Anthem Inc | Trimmed | −45,000 | −$5.64M | 1.1% |
Showing the 10 largest of 102 changes.
quarter ended June 30, 2016 · filed November 04, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| M Medivation | Trimmed | −255,000 | −$15.4M | 0.2% |
| CC Cigna Corporation | Exited | −100,000 | −$13.7M | — |
| SS SPDR Series Trust | Exited | −250,000 | −$12.9M | — |
| IT Ishares Tr | Exited | −100,000 | −$11.1M | — |
| SP Shire PLC | New | +60,000 | +$11M | 4.5% |
| SS SPDR S&P 500 ETF Tr | Exited | −50,000 | −$10.3M | — |
| A Anthem Inc | New | +70,000 | +$9.19M | 3.7% |
| Medtronic PLC | Exited | −100,000 | −$7.5M | — |
| BI Baxter Intl Inc | Trimmed | −155,000 | −$7.01M | 2.5% |
| AP Alexion Pharmaceuticals Inc | New | +50,000 | +$5.84M | 2.4% |
Showing the 10 largest of 107 changes.
Loading...
